Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Leukemia 15Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Philadelphia Chromosome 4Leukemia, Myeloid 4Bone Marrow Diseases 4Neoplasms 3Myeloproliferative Disorders 3Hematologic Diseases 3Melanoma 2Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Blast Crisis 2Synovitis, Pigmented Villonodular 1Recurrence 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Leukemia, Myeloid, Accelerated Phase 1Hypereosinophilic Syndrome 1Glioma 1

Interventions

pexidartinib 3nilotinib 1cabiralizumab 1Tolbutamide 1Midazolam 1Bro protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Synovitis, Pigmented Villonodular × nilotinib × Clear all
NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡